MKPPL is a Manufacturer of Pre-finished formulation Intermediates accredited by the European Union & WHO for GMP compliance. Our USP is manufacturing of Bioequivalent products using an Aqueous-layering system.
Established in the year 2004, MKPPL had initiated its operations with a single thereuptic group with its supplies to certain semi-regulated markets. With the EU approval in the year 2007, MKPPL had transmuted its operations into a regulatory compliant manufacturer and today, MKPPL is one of the leading manufacturers of PFI’s from India.
MKPPL which had already mastered the Macro, Micro & MUPS arenas is now quickly taking its steps towards Nano Technology which would be a major breakthrough in NDDS.
34+
Products
With a lineup of more than 34 products, Our Therapeutic segment includes Anti-Ulcerants, Anti Fungal, Antibiotics, Anti Obesity, Anti Depressant, Anti Inflammatory, Alpha-blockers, Immune Suppressants and Anti-emetic (during chemotherapy) in the developed/commercialized category and development pipeline includes Mitotic Inhibitors, Carbonic anhydrase inhibitors and Triazole anti-fungals.
With a lineup of more than 34 products, Our Therapeutic segment includes Anti-Ulcerants, Anti Fungal, Antibiotics, Anti Obesity, Anti Depressant, Anti Inflammatory, Alpha-blockers, Immune Suppressants and Anti-emetic (during chemotherapy) in the developed/commercialized category and development pipeline includes Mitotic Inhibitors, Carbonic anhydrase inhibitors and Triazole anti-fungals.
At Murli Krishna Pharma, it is our endeavor to provide the best quality products to the Industry at competitive prices that will provide cost effective therapeutic agents to the developed as well as under developed world.
We have a definite vision and we need to achieve our vision through cogent strategies and conduct a periodical review of the same to ensure that we do not deviate from the track.
Ethical business practices is the MANTRA of our company and through our innovations and research, we would like to grow and support the clients in their growth mission too. These values will spurt the growth of Murli Krishna Pharma and make Murli Krishna Pharma a Global Leader in Drug Delivery Technologies
— Satya Vadlamani, Chairperson and Managing Director
MKPPL which is a DSIR Certified/Recognized R&D, is actively engaged in devising innovative drugs solutions with thoughtful selection of Excipients using a cogent Matrix. The R&D team has devised unique techniques to layer poorly soluble drugs using aqueous media.
A pellet based approach has been employed for immune suppressants. The pilot results indicate that the in vivo results match with the innovator in case of Tacrolimus.
A dedicated team has been engaged for devising Nano based developments (Nano Particles) for applications including Injectables, Respules etc. covering the Oncological, Ophthalmological and Corticosteroid categories.
To be a Global Leader in Drug Delivery Technologies, we need to be ahead of the competition. For this, we have committed ourselves to constant innovation and maintaining World Class Quality Standards .
Our goal is to ease the patient's discomfort and lead them to heal faster. With a complete focus on the customer, continuous improvement on processes combined with teamwork and collaboration, we are destined to spur exponential growth for our company in terms of value and revenue.
— Dr. Vijay K. Shastri, Director and Technical Head
Mission
To provide the best quality products at competitive prices through integration, research, innovation & development. To be an ethically responsible company and work towards the growth of our clients, our country and our employees To continually innovate and develop indigenous drug delivery systems that shall propel the company as one of the leading drug manufacturing companies in the world
Vision
To be a Global Leader in Drug Delivery Technologies through Research & Innovation
Values
• Innovation • Ensure Quality • R&D • Customer Focus • Continuous Improvement • Ambition to succeed • Collaboration • Teamwork
Some of our clients include
Product | Percentage | Mesh Size | Release Type | Target Formulations | |
|---|---|---|---|---|---|
 | 15% , 40% | - | Immediate Release | Capsules | Injectables | |
 | 20% , 40% , 7.5% | - | Tastemasked | Capsules | Suspension | Tablets | |
 | 1% , 10mg | - | - | Eye drops | Suspension | |
 | 0.8 % | - | Extended Release | Capsules | Suspension | Tablets | |
 | - | - | - | Suspension | |
| 0.8 % | - | - | Dry Powder Inhaler | |
| - | - | - | Inhalation | Oral | |
 | 27.5%, 30%, 33%, 42%, 43% | 30#100 , 30#80 | Tastemasked | Capsules | Suspension | Tablets | |
| 8.5%,13.33%,17%, 20% | - | Delayed Release | Capsules | |
 | 17% , 20% , 23% | - | Dual Delayed Release | Capsules |
Contact us for more information, support or any other queries.
